Evidence map›Paper›PMID 36631484›Full record

ArticleScientific reports2023

Simplifying the detection and monitoring of protein glycosylation during in vitro glycoengineering.

Matthew J Saunders, Robert J Woods, Loretta Yang

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Matthew J SaundersLectenz Bio, 111 Riverbend Rd, Athens, GA, 30602, USA.
Robert J WoodsComplex Carbohydrate Research Center, University of Georgia, 315 Riverbend Rd, Athens, GA, 30602, USA.
Loretta YangLectenz Bio, 111 Riverbend Rd, Athens, GA, 30602, USA. lyang@lectenz.com.
Lectenz Bio (United States) · USUniversity of Georgia · US

Funding

Transitioning GLYCAM-Web to a self-sustaining carbohydrate modeling serviceR24GM136984 · NIGMS · UNIVERSITY OF GEORGIA · PI WOODS, ROBERT J · 2020 to 2022
$1.4M
Adapting multiplex microspheres to analyze glycosylation features by flow cytometryU01CA221213 · NCI · LECTENZ BIO, INC. · PI YANG, LORETTA · 2017 to 2019
$836k
A rapid method for monitoring in vitro glycoengineeringR43GM123863 · NIGMS · LECTENZ BIO, INC. · PI YANG, LORETTA · 2017 to 2018
$300k
NCI NIH HHS U01 CA221213NIGMS NIH HHS R24 GM136984NIGMS NIH HHS R43 GM123863
6 · The paper itself

Abstract

The majority of mammalian proteins are glycosylated, with the glycans serving to modulate a wide range of biological activities. Variations in protein glycosylation can have dramatic effects on protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, as well as serum half-life. The glycosylation of therapeutic biologicals is a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency. Notably, many factors can affect the composition of the glycans during glycoprotein production, and variations in glycosylation are among the leading causes of pharmaceutical batch rejection. Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production. Here we report a simplified approach to assist in monitoring glycosylation features during glycoprotein engineering, that employs flow cytometry using fluorescent microspheres chemically coupled to high-specificity glycan binding reagents. In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release. The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench. The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.

Indexed as

AntibodiesGlycoproteinsAnimalsGlycosylationMammalsMass SpectrometryPolysaccharidesAntibodiesGlycoproteinsPolysaccharides

Identifiers

PMID36631484
PMCPMC9834283
OpenAlexW4315646123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.